4.7 Article

Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer

Journal

ONCOLOGIST
Volume 18, Issue 2, Pages 123-133

Publisher

WILEY
DOI: 10.1634/theoncologist.2012-0397

Keywords

Breast cancer; Subtype; Gene expression; Triple-negative; basal-like

Categories

Funding

  1. National Cancer Institute [P50-CA58223-09A1]
  2. National Institutes of Health [RO1-CA138255]
  3. Breast Cancer Research Foundation
  4. Sociedad Espanola de Oncologia Medica

Ask authors/readers for more resources

Triple-negative (TN) and basal-like (BL) breast cancer definitions have been used interchangeably to identify breast cancers that lack expression of the hormone receptors and overexpression and/or amplification of HER2. However, both classifications show substantial discordance rates when compared to each other. Here, we molecularly characterize TN tumors and BL tumors, comparing and contrasting the results in terms of common patterns and distinct patterns for each. In total, when testing 412 TN and 473 BL tumors, 21.4% and 31.5% were identified as non-BL and non-TN, respectively. TN tumors identified as luminal or HER2-enriched (HER2E) showed undistinguishable overall gene expression profiles when compared versus luminal or HER2E tumors that were not TN. Similar findings were ob-served within BL tumors regardless of their TN status, which suggests that molecular subtype is preserved regardless of individual marker results. Interestingly, most TN tumors identified as HER2E showed low HER2 expression and lacked HER2 amplification, despite the similar overall gene expression profiles to HER2E tumors that were clinically HER2-positive. Lastly, additional genomic classifications were examined within TN and BL cancers, most of which were highly concordant with tumor intrinsic subtype. These results suggest that future clinical trials focused on TN disease should consider stratifying patients based upon BL versus non-BL gene expression profiles, which appears to be the main biological difference seen in patients with TN breast cancer. The Oncologist 2013;18:123-133

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available